Article in Medicina (Kaunas, Lithuania), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Akif DoğanDepartment of Medical Oncology, Health Science University, Sancaktepe, Şehit Prof Dr. İlhan Varank Training Research Hospital, Istanbul 34785, Turkey.ORCID 0000-0003-4275-2414
Nurullah İlhanDepartment of Medical Oncology, Health Science University, Sancaktepe, Şehit Prof Dr. İlhan Varank Training Research Hospital, Istanbul 34785, Turkey.
Goncagül AkdağDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-6221-0623
Sedat YıldırımDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-2423-6902
Mustafa SeyyarDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Turkey.ORCID 0000-0002-4841-7994
Zeynep Yüksel YaşarDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-2929-5039
Hande Nur ErölmezDepartment of Medical Oncology, Health Science University, Sancaktepe, Şehit Prof Dr. İlhan Varank Training Research Hospital, Istanbul 34785, Turkey.ORCID 0009-0004-3791-9157
Heves SürmeliDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0003-1604-8466
Buğra ÖztosunDepartment of Medical Oncology, Faculty of Medicine, Medeniyet University, Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34700, Turkey.
Özlem Nuray SeverDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0003-3462-9360
Hatice OdabaşDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-5757-4705
Mahmut Emre YıldırımDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-5360-5949
Devrim ÇabukDepartment of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli 41001, Turkey.ORCID 0000-0002-7871-6311
Nedim TuranDepartment of Medical Oncology, Health Science University, Kartal Dr. Lütfi Kirdar City Hospital, Istanbul 34865, Turkey.ORCID 0000-0002-1140-8779
Mahmut GümüşDepartment of Medical Oncology, Faculty of Medicine, Medeniyet University, Prof. Dr. Süleyman Yalçın City Hospital, Istanbul 34700, Turkey.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6AdultAgedAge of OnsetAminopyridinesFemaleHumansMiddle AgedPiperazinesProtein Kinase InhibitorsPurinesPyridinesRetrospective StudiesAminopyridinesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesProtein Kinase InhibitorsPurinesPyridinesribociclibCDK 4/6 inhibitorsearly-onset breast cancerpremenopausal metastatic breast cancervery early-onset breast cancer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Evaluating the Effectiveness of Cyclin-Dependent Kinase 4/6 Inhibitors in Early- and Very Early-Onset Metastatic Breast Cancer: A Multicenter Study. · full record | OpenQuestion